Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Arcus Biosciences, Inc. Common Stock (NY: RCUS )

13.10 +0.40 (+3.15%)
Official Closing Price Updated: 7:00 PM EST, Feb 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Arcus Biosciences, Inc. Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Arcus Biosciences to Participate in Two Upcoming Investor Conferences
From Arcus Biosciences
Via Business Wire
Arcus Biosciences Announces New Employment Inducement Grants
From Arcus Biosciences
Via Business Wire
Critical Insights From Arcus Biosciences Analyst Ratings: What You Need To Know
Via Benzinga
Recap: Arcus Biosciences Q4 Earnings
Via Benzinga
Arcus Biosciences Reports Fourth-Quarter and Full-Year 2023 Financial Results and Provides a Pipeline Update
From Arcus Biosciences
Via Business Wire
Earnings Scheduled For February 21, 2024
Companies Reporting Before The Bell • Gatos Silver (NYSE:GATO) is estimated to report quarterly earnings at $0.09 per share on revenue of $83.00 million. 
Via Benzinga
Preview: Arcus Biosciences's Earnings
Via Benzinga
Key Takeaways From Arcus Biosciences Analyst Ratings
Via Benzinga
Arcus Biosciences Announces New Employment Inducement Grants
From Arcus Biosciences
Via Business Wire
Arcus Biosciences to Host Conference Call to Discuss Fourth-Quarter and Full-Year 2023 Financial Results and Pipeline Updates
From Arcus Biosciences
Via Business Wire
$320M Bet On This Healthcare Stock? Check Out These 3 Stocks Insiders Are Buying
Although U.S. stocks closed lower on Wednesday, there were a few notable insider trades. 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
We're starting off trading on Tuesday with a look into the biggest pre-market stock movers traders need to keep an eye on today! 
Via InvestorPlace
What 9 Analyst Ratings Have To Say About Arcus Biosciences
Via Benzinga
Arcus Biosciences: Q3 Earnings Insights
Via Benzinga
Pharma Giant Gilead Raises Stake In Cancer-Focused Arcus Biosciences, Stock Soars
Arcus Biosciences sees a 17.1% surge as Gilead Sciences amends collaboration, investing $320M at $21.00/share. Accelerate joint programs in cancer therapy. 
Via Benzinga
Gilead and Arcus Announce Amended Collaboration and Equity Investment
From Arcus Biosciences
Via Business Wire
Arcus Biosciences Announces New Employment Inducement Grants
From Arcus Biosciences
Via Business Wire
Data from a Phase 1b Study of Quemliclustat-Based Regimens Showed Promising Overall Survival in Treatment-Naïve Metastatic Pancreatic Cancer
From Arcus Biosciences
Via Business Wire
Arcus Biosciences Announces New Employment Inducement Grants
From Arcus Biosciences
Via Business Wire
Exelixis and Arcus Biosciences Announce Clinical Trial Collaboration to Evaluate Zanzalintinib in Combination with AB521 in Patients with Advanced Renal Cell Carcinoma
From Arcus Biosciences
Via Business Wire
Arcus Biosciences Announces New Employment Inducement Grants
From Arcus Biosciences
Via Business Wire
From laggards to leaders: Small caps on the rise
Despite large-cap dominance, signs suggest a shift to small-cap leadership. Valuations, positive Q3 results, and historical patterns point to potential gains. 
Via MarketBeat
Arcus Biosciences to Participate in the 6th Annual Evercore ISI HealthCONx Conference
From Arcus Biosciences
Via Business Wire
Arcus Biosciences Announces New Employment Inducement Grants
From Arcus Biosciences
Via Business Wire
Arcus Biosciences Reports Third Quarter 2023 Financial Results and Provides a Pipeline Update
From Arcus Biosciences
Via Business Wire
Positive News For Gastric Cancers - Gilead/Arcus Biosciences' Combination Cancer Therapy Shows Encouraging Clinical Activity
Gilead Sciences Inc (NASDAQ: GILD) and Arcus Biosciences Inc (NYSE: RCUS) announced that domvanalimab plus zimberelimab and chemotherapy showed encouraging overall response rate (ORR) and six-month... 
Via Benzinga
Gilead and Arcus Announce New Data Showing Encouraging Clinical Activity of Anti-TIGIT Domvanalimab-Containing Regimen as First-line Treatment for Upper GI Cancers
From Gilead Sciences, Inc.
Via Business Wire
Earnings Scheduled For November 7, 2023
Companies Reporting Before The Bell • CorEnergy Infr Tr (NYSE:CORR) is estimated to report earnings for its third quarter. 
Via Benzinga
Arcus Biosciences Announces New Employment Inducement Grants
From Arcus Biosciences
Via Business Wire
Arcus Biosciences to Present Data from Ongoing EDGE-Gastric Study at ASCO Plenary and to Report Third-Quarter Financial Results on November 7
From Arcus Biosciences
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.